<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37235337</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1536-3686</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>4</Issue><PubDate><MedlineDate>2023 Jul-Aug 01</MedlineDate></PubDate></JournalIssue><Title>American journal of therapeutics</Title><ISOAbbreviation>Am J Ther</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Vaccination Is the Most Promising Intervention for Long COVID.</ArticleTitle><Pagination><StartPage>e372</StartPage><EndPage>e373</EndPage><MedlinePgn>e372-e373</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MJT.0000000000001641</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manu</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Zucker School of Medicine at Hofstra/ Northwell, Hempstead, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Service, South Oaks Hospital, Amityville, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Ther</MedlineTA><NlmUniqueID>9441347</NlmUniqueID><ISSNLinking>1075-2765</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>26</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37235337</ArticleId><ArticleId IdType="doi">10.1097/MJT.0000000000001641</ArticleId><ArticleId IdType="pii">00045391-990000000-00154</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gibbone G, Koroshetz W, Auchincloss H. RECOVER: what clinical research comes next for helping people with long COVID. Available at: https://directorsblog.nih.gov/2023/03/02/recover-what-clinical-research-comes-next-for-helping-people-with-long-covid . Accessed April 25, 2023.</Citation></Reference><Reference><Citation>Bonilla H, Peluso MJ, Rodgers K, et al. Therapeutic trials for long COVID-19: a call to action from the interventions taskforce of the RECOVER initiative. Front Immunol. 2023;14:1129459.</Citation></Reference><Reference><Citation>Cohrs R, Ladyzhets B. The NIH has pured $1 billion into long Covid research &#x2013; with little to show for it. Available at: https://www.statnews.com/2023/04/20/long-covid-nih-billion/#:&#x223c;:text=NIH%20RECOVER's%20spending&amp;text=In%202020%2C%20Congress%20made,Covid%20was%20virtually%20unheard%20of . Accessed April 25, 2023.</Citation></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long COVID symptoms after COVID-19 vaccination: community based cohort study. BMJ. 2022;377:e069676.</Citation></Reference><Reference><Citation>Mumtaz A, Sheikh AAE, Khan AM, et al. COVID-19 vaccine and long COVID: a scoping review. Life (Basel). 2022;12:1066. doi.</Citation></Reference><Reference><Citation>Tofarides AG, Christaki E, Milionis H, Nikolopoulos GK. Effect of vaccination against SARS-CoV-2 on long COVID-19: a narrative review. Life (Basel). 2022;12:2057.</Citation></Reference><Reference><Citation>Byambasuren O, Stehlik P, Clark J, et al. Effect of COVID-19 vaccination on long COVID: systematic review. BMJ Med. 2023;2:e000385.</Citation></Reference><Reference><Citation>Webb GR. Tuberculosis. In. Cecil RL. A Text-Book of Medicine B American Authors. W.B Saunders Company; 1928:159&#x2013;242.</Citation></Reference><Reference><Citation>Currie GA. Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. Br J Cancer. 1972;26:141&#x2013;153.</Citation></Reference></ReferenceList><ReferenceList><Reference><Citation>Berd D, Maguire Jr HC, Mastrangelo MJ. Treatment of human melanoma with a hapten-modified autologous vaccine. Ann N Y Acad Sci 1993:690:147&#x2013;152.</Citation></Reference></ReferenceList><ReferenceList><Reference><Citation>Rose Lukesh N, Middleton DD, Bachelder EM, Ainslie KM. Particle-Based therapies for antigen specific treatment of type 1 diabetes. Int J Pharm. 2023;631:122500.</Citation></Reference><Reference><Citation>Selaa M. Specific vaccines against autoimmune diseases. C R Acad Sci III. 1999;322:933&#x2013;938.</Citation></Reference><Reference><Citation>Liu X, Munro APS, Wright A, et al., COV-BOOST study group. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. J Infect. 2023:S0163-4453()00247-5.</Citation></Reference><Reference><Citation>Walmsley SL, Szadkowski L, Wouters B, et al. COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series. iScience. 2023;26:106506.</Citation></Reference><Reference><Citation>Augustinussen MH, Tylden GD, Rinaldo CH. Dynamics of SARS-CoV-2 spike-IgG throughout three COVID-19 vaccination regimens: a 21-month longitudinal study of 82 Norwegian healthcare workers. Viruses. 2023;15:619.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>